Verastem, Inc. (VSTM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Verastem reported revenue of $30.9M, up 209.1% from $10.0M the year before. Net income was -$209.5M (a -677.6% net margin), or -$3.02 per diluted share. Gross margin was -550.3% and operating margin was -550.3%. Operating activities generated -$137.5M of cash, leaving -$137.5M of free cash flow. At fiscal year end, Verastem held $246.4M in total assets against $189.2M in total liabilities, including $205.0M of cash and equivalents.
Open the full interactive Verastem financials → Quarterly statements, key ratios, valuation history and price charts.
Verastem Key Stats
| Share Price | $7.45 |
|---|---|
| Market Cap | $745.9M |
| Revenue YoY Growth | +209.1% |
| 52-Week Range | $3.45 – $10.64 |
| Shares Outstanding | 100.1 million (basic, 2026 Q2) |
Verastem Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $88.5M | $2.1M | $2.6M | $0 | $10.0M | $30.9M |
| Cost of Goods Sold | $137.9M | — | — | — | — | $201.0M |
| Gross Profit | -$49.4M | — | — | — | — | -$170.1M |
| Operating Income | -$49.4M | -$61.4M | -$72.9M | -$92.1M | -$115.0M | -$170.1M |
| Pre-Tax Income | -$67.5M | -$71.2M | -$73.8M | -$87.4M | -$130.5M | -$209.5M |
| Income Tax | $194,000 | $0 | $0 | — | $185,000 | — |
| Net Income | -$67.7M | -$71.2M | -$73.8M | -$87.4M | -$130.6M | -$209.5M |
| Diluted EPS | -$5.28 | -$4.92 | -$4.56 | -$3.93 | -$3.66 | -$3.02 |
Verastem Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.2M | $17.5M | $18.7M | $40.1M |
| Net Income | -$98.5M | -$32.9M | -$36.6M | -$34.7M |
| Diluted EPS | -$1.35 | -$0.47 | -$0.46 | -$0.35 |
Verastem Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $67.8M | $21.3M | $74.9M | $77.9M | $88.8M | $205.0M |
| Current Assets | $144.9M | $105.7M | $92.9M | $143.7M | $95.0M | $223.4M |
| Total Assets | $154.3M | $108.7M | $95.0M | $149.7M | $101.5M | $246.4M |
| Current Liabilities | $17.1M | $18.6M | $21.7M | $26.4M | $31.0M | $72.3M |
| Total Long-Term Debt | $19.1M | $249,000 | $24.5M | $40.1M | $40.7M | $76.3M |
| Total Liabilities | $39.1M | $21.1M | $47.7M | $71.2M | $130.4M | $189.2M |
| Shareholders' Equity | $115.3M | $87.6M | $47.4M | $57.4M | -$28.9M | $57.2M |
Verastem Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$33.5M | -$53.5M | -$63.7M | -$86.5M | -$104.8M | -$137.5M |
| Cash From Investing | -$47.4M | $87,000 | $66.2M | -$44.4M | $60.0M | -$9.6M |
| Cash From Financing | $69.6M | $6.9M | $51.8M | $134.2M | $54.8M | $263.3M |
| Free Cash Flow | -$33.5M | -$53.7M | -$63.9M | -$86.7M | -$104.8M | -$137.5M |
Figures from Verastem's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Verastem financials page for every line item.
Verastem Company Profile
| Ticker | VSTM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Needham, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001526119 |
Frequently Asked Questions
What was Verastem's revenue in fiscal 2025?
Verastem (VSTM) reported revenue of $30.9M for fiscal 2025.
What is Verastem's annual revenue history?
Verastem's annual revenue by fiscal year: 2020: $88.5M; 2021: $2.1M; 2022: $2.6M; 2023: $0; 2024: $10.0M; 2025: $30.9M.
What was Verastem's net income in fiscal 2025?
Verastem reported net income of -$209.5M for fiscal 2025.
What was Verastem's earnings per share (EPS) in fiscal 2025?
Verastem's diluted EPS was -$3.02 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Verastem generate in fiscal 2025?
Verastem generated -$137.5M of free cash flow in fiscal 2025.
What was Verastem's revenue last quarter?
In its most recent reported quarter (2026 Q2), Verastem reported revenue of $40.1M.
How much debt does Verastem have?
Verastem reported $76.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Verastem are outstanding?
Verastem reported a weighted average of 100.1 million basic shares outstanding in 2026 Q2.
What is Verastem's market cap?
Based on its latest closing price, Verastem (VSTM) has a market capitalization of about $745.9M.
When does Verastem's fiscal year end?
Verastem's fiscal year end, as registered with the SEC, is December 31.
Where is Verastem headquartered?
Verastem lists its business address in Needham, Massachusetts in its SEC filings.